In January 2023, the company had announced the successful completion of the full set of clinical studies of its proposed rituximab biosimilar candidate DRL RI, with the intention to file in the United States, European Union and other regionsFollowing dossier submission in April 2023, the regulatory agencies have now.
Dr Reddys Labs (RDY) Completes Full Set of Studies for DRL_RI in US and EU streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Hyderabad: Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced that it has successfully completed the full set of clinical studies of its proposed rituximab biosimilar candidate, DRL RI, for filing in highly regulated markets such as the United States, Europe and other regions.